EICHOR
● Completed
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Condition: Glaucoma · Ocular Hypertension · Sponsor: Laboratoires Thea
About this study
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (24)
| Arizona Advanced Eye Research Institute | Glendale, Arizona, United States | — |
| Global Research Management, Inc. | Glendale, California, United States | — |
| United Medical Research Institute | Inglewood, California, United States | — |
| Eye Research Foundation | Newport Beach, California, United States | — |
| Visionary Research Institute | Newport Beach, California, United States | — |
| North Bay Eye Associates | Petaluma, California, United States | — |
| Sacramento Eye Consultants, A Medical Corporation | Sacramento, California, United States | — |
| Wolstan and Goldberg Eye Associates | Torrance, California, United States | — |
| Segal Drug Trials, Inc | Delray Beach, Florida, United States | — |
| East Coast Institute for Research, LLC | Jacksonville, Florida, United States | — |
| Shettle Eye Research, Inc. | Largo, Florida, United States | — |
| Mild Florida Eye Center | Mt. Dora, Florida, United States | — |
+ 12 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.